Shows
EASL Video PodcastsEASL Studio Podcast: Decoding AASLD The Liver Meeting: Trends Shaping HepatologyWhat were the key takeaways from this year’s AASLD The Liver Meeting? In this episode, experts unpack the most impactful studies, clinical insights, and emerging trends shaping the future of hepatology. From liver cancer breakthroughs to MASLD, ALD, and beyond.
Moderator: Debbie Shawcross
Speakers: Saul Karpen, Allison Kwong, Mazen Noureddin
All EASL Studio Podcasts are available on EASL Campus.
Click here to see all EASL Video Podcasts on Apple Podcasts.
2025-12-0436 min
EASL PodcastsEASL Studio Podcast: Decoding AASLD The Liver Meeting: Trends Shaping HepatologyWhat were the key takeaways from this year’s AASLD The Liver Meeting? In this episode, experts unpack the most impactful studies, clinical insights, and emerging trends shaping the future of hepatology. From liver cancer breakthroughs to MASLD, ALD, and beyond.Moderator: Debbie ShawcrossSpeakers: Saul Karpen, Allison Kwong, Mazen NoureddinAll EASL Studio Podcasts are available on EASL Campus.Click here to see all EASL Video Podcasts on Apple Podcasts.
2025-12-0435 min
Wysdom Radio™Portal Hypertension, TIPS, and RTO—Latest AASLD Guidance🎙️ Wysdom Radio: Portal Hypertension, TIPS, and RTO—Latest AASLD Guidance
This episode breaks down the critical differences between the two main endovascular strategies for managing variceal bleeding in patients with portal hypertension:
TIPS (Transjugular Intrahepatic Portosystemic Shunt): A procedure that acts as an internal bypass to lower the overall portal pressure.
New Guidance: Covered stents are now standard, and smaller 8mm stents are preferred to minimize the risk of Hepatic Encephalopathy (HE).
Trade-Off: It reduces the risk of bleeding but increases the risk of HE (brain fog/confusion).
RTO/ATO (Retr...
2025-12-0316 min
Better Edge : A Northwestern Medicine podcast for physicians2025 AASLD Updates from Northwestern Medicine ExpertsIn this episode of Better Edge, Sean W. P. Koppe, MD, moderates a panel of Northwestern Medicine hepatologists as they discuss recent scientific updates from the American Association for the Study of Liver Diseases (AASLD) annual meeting held in November 2025. The conversation addresses key updates in the management of patients with cirrhosis, MASLD, HCC, alcohol liver disease, cholestatic liver diseases and autoimmune hepatitis that were presented at the meeting.
2025-11-2000 min
Healthier World with Quest Diagnostics23 - Instant Insights: Decoding MASLD (7 min)This special episode of Healthier World designed to give you Instant Insights discusses the importance of screening and managing fatty liver disease, a condition affecting 1 in 3 Americans and over 70% of patients with type 2 diabetes. The episode covers the transition from the term NAFLD to MASLD, discusses the AACE-recommended testing algorithm for MASLD using the fibrosis-4 (FIB-4) score and the enhanced liver fibrosis (ELF) and highlights the importance of early identification and intervention for proper management of underlying metabolic conditions.
This episode will
Review the implications of the shift in terminology from NAFLD to MASLD (1:00)
Discuss the...
2025-10-0606 min
What's it Worth? A Journal Club PodcastS3E5 (#21) Empagliflozin Meets MASLD: Hope, Hype, or Hypothesis?Welcome back to What's it Worth! Join your hosts, Dr. Diana Langworthy and Dr. Peyton Braun (PGY1 Pharmacy Resident), as we sift through strengths and limitations of at trial assessing the effects of empagliflozin on nonalcoholic fatty liver disease. The authors sought to quantify the impact of Sodium Glucose Cotransporter 2 - inhibitors (SGLT2i's) on Metabolic Dysfunction Associated Liver Disease (MASLD). This episode is full of EBP detective moments - dissecting trial language to get a clear picture of the story. Let's dive in and see what its worth! Key Points MASLD is a condition marked...
2025-06-0350 min
Surfing the MASH TsunamiS6 - E4 - Reasons for optimism in MASLD drug development and patient advocacy00:00:00 - Surf's Up: Season 6 Episode 4 Surfing the MASH Tsunami concludes its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on pivotal messages that attendees took away from the conference and what messages they would like to share with listeners. Our newsmaker, Fatty Liver Alliance and CEO Mike Betel, discusses the lessons he has taken from being invited to a far wider swath of conferences this year and shares the messages he delivers to these new audiences. Finally, our expert, hepatology research and key opinion leader Mazen Noureddin, discusses r...
2025-04-111h 12Surfing the MASH TsunamiS6 - E3 - Drugs and Diagnostics Evolve as the FDA Devolves00:00:00 - Surf's Up: Season 6 Episode 3Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on what studies on bariatric surgery and drugs in development can tell us about future treatment and explore some clinical trial questions. Our newsmaker, HistoIndex Director of Clinical Development Yukti Choudhury, introduces us to FibroSIGHT, which provides clinicians with highly precise biopsy analysis. Finally, our expert, Global Liver Institute Vice President, Liver Programs Jeff McIntyre, discusses the implications of recent US government job cuts on future MASH treatment options...
2025-04-041h 12Surfing the MASH TsunamiS6 - E2 - MetALD Epidemiology, MASLD Mortality and a PCP "Unicorn"00:00:00 - Surf's Up: Season 6 Episode 2Surfing the MASH Tsunami continues its coverage of the AASLD Emerging Trends Conference on MASLD, MetALD and ALD. This week, the panelists focus on disease epidemiology and what it can teach us about the relative importance of alcohol and diet on disease progression. Our newsmaker, hepatology KOL and frequent Surfer Hannes Hagstrom, discusses what a recent paper demonstrates about the impact of MASLD on 15-year mortality and cause of death and how this information can improve patient care. Finally, our Expert, Shelbyville, Indiana internist Emily Ann Andeya, discusses her path from practicing...
2025-03-281h 11Surfing the MASH TsunamiS6 - E1: Two Multispecialty February Conferences and Europe Prepares for Resmetirom00:00:00 - Surf's Up! Season 6 Episode 1SurfingMASH kicks off our sixth season in our new format, with three major elements to each episode. This week's Roundtable and Newsmakers segments focused on two recent conferences that took a multispecialty perspective on the range of medical and psychological issues affecting steatotic liver disease (a new concept specialty: steatology.") Our Expert this week is our co-host Jörn Schattenberg, discussing the educational and conceptual challenges of readying Europe for the EMA approval of resmetirom later this year.00:03:58 - Introductions and GroundbreakersHost Roger Green describes the new v...
2025-03-211h 13
GHAPPcastKOL Interview: Can You Discuss Any Recent Breakthroughs in the Management of Cirrhosis?In this video, Sherona Bau, NP, at Pfleger Institute at UCLA, shares the latest advancements in cirrhosis management, including newly FDA-approved medications and updated AASLD (American Association for the Study of Liver Diseases) guidelines. While there are still limited medications specifically for cirrhosis, recent developments provide promising options for patients with liver disease.One key update is in the management of portal hypertension, where AASLD now recommends non-selective beta blockers like carvedilol for variceal bleeding prophylaxis, particularly due to its vasodilatory effects. Patients with medium or large varices are advised to take these medications to reduce bleeding...
2025-02-1902 min
Medicine via myPodPractice Point CME - Rare Disease Podcast: Episode 7 - Clinical Clips® from AASLD 2024: Key Breakthroughs in the Treatment of Primary Biliary Cholangitis - Part 2Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.Launch Date: November 26, 2024Release Date: November 26, 2024Expiration Date: October 31, 2025FACULTYAshwani K. Singal, MD, MS, FACG, FAASLD, AGAFProfessor of Medicine, University of LouisvilleTransplant Hepatologist and Staff PhysicianTraeger Transplant Center and Jewish Hospital
2025-01-2110 min
Practice Point® CME Podcasts: Expert Discussions in Rare Diseases™Episode 7 - Clinical Clips® from AASLD 2024: Key Breakthroughs in the Treatment of Primary Biliary Cholangitis - Part 2Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.Launch Date: November 26, 2024Release Date: November 26, 2024Expiration Date: October 31, 2025FACULTYAshwani K. Singal, MD, MS, FACG, FAASLD, AGAFProfessor of Medicine, University of LouisvilleTransplant Hepatologist and Staff PhysicianTraeger Transplant Center and Jewish Hospital
2025-01-2110 min
Practice Point® CME Podcasts: Expert Discussions in Rare Diseases™Episode 6- Clinical Clips® from AASLD 2024: Key Breakthroughs in the Treatment of Primary Biliary Cholangitis - Part 1 Several new developments in primary biliary cholangitis (PBC) on available and emerging therapies were presented at AASLD 2024. In these podcasts, Dr. Ashwani K. Singal will discuss the most important breakthroughs in the understanding and treatment of PBC and will provide guidance on their impact.Launch Date: November 26, 2024Release Date: November 26, 2024Expiration Date: October 31, 2025FACULTYAshwani K. Singal, MD, MS, FACG, FAASLD, AGAFProfessor of Medicine, University of LouisvilleTransplant Hepatologist and Staff PhysicianTraeger Transplant Center and Jewish Hospital
2025-01-2010 min
Decera Clinical Education Infectious Disease PodcastKey PBC Studies From AASLD 2024In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:ELATIVE, a phase III trial of elafibranor for PBCRESPONSE, a phase III trial of seladelpar for PBCASSURE, another phase III trial of seladelpar for PBCPresenter:Sonal Kumar, MD, MPHDirector, Clinical Gastroenterology and HepatologyAssistant Professor of MedicineWeill Cornell Medical CollegeNew York, New YorkLink to full program:https://bit.ly/41tvSDuGet access to all of our new podcasts by subscribing to the C...
2025-01-0720 min
Decera Clinical Education Medical Specialties PodcastKey PBC Studies From AASLD 2024In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:ELATIVE, a phase III trial of elafibranor for PBCRESPONSE, a phase III trial of seladelpar for PBCASSURE, another phase III trial of seladelpar for PBCPresenter:Sonal Kumar, MD, MPHDirector, Clinical Gastroenterology and HepatologyAssistant Professor of MedicineWeill Cornell Medical CollegeNew York, New YorkLink to full program:https://bit.ly/41tvSDuGet access to all of our new podcasts by subscribing to the C...
2025-01-0720 min
The Other 80Breaking up the Deadly Organ Transplant Monopoly with Donna CryerOn so many issues, Congress has not been willing or able to act. But when faced with horrifying stories of death and mismanagement, Congress finally passed legislation to reform the US organ transplant system. They did so because people like Donna Cryer, a transplant recipient and patient advocate, demanded a better system for Americans who need lifesaving organ transplants. Now, as the new law moves into implementation, the work continues. In this episode, Donna and I discuss:The new legislation that is breaking up the deadly organ transplant monopolyHow ignoring the expertise and insights of patients...
2024-11-2735 minSurfing the MASH TsunamiS5 - E21.6 - From The Vault: Comments On The 2023 AASLD Revised Practice GuidanceThis week's vault conversation looks back 17 months when Ken Cusi joined co-hosts Louise Campbell, Jörn Schatenberg and Roger Green to discuss the revised AASLD Practice Guidance that had been issued the previous week. At the time, here was SurfingMASH's summary of the conversation: Late last week, AASLD published new practice guidance on the clinical assessment and management of NAFLD. The Surfers convene with Ken Cusi, who contributed to the previous iteration published in 2018, to explore its key features and implications. The updated document reflects the many advances pertinent to any practitioner caring for patients with NAFLD. T...
2024-06-3011 min
TIME to Talk - Science & MedicineWhat every young women should know about alcohol consumptionGet to know Dr. Jennifer Flemming – Dr. Flemming is an Associate Professor of Medicine and Public Health Sciences at Queen’s University with clinical training in gastroenterology, hepatology and liver transplantation. After completing her Internal Medicine and Gastroenterology training at Queen’s University, she completed two years of advanced hepatology and a Master’s in Clinical Research at the University of California San Francisco.
In her clinical practice she manages a wide variety of patients with chronic liver disease from early disease stages to decompensated cirrhosis, hepatocellular carcinoma and liver transplant. She is a clinician scientist who leads a...
2024-04-0340 min
Decera Clinical Education Infectious Disease PodcastNew Audio Updates: CCO Independent Conference Coverage of Hepatitis B at AASLD 2023In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:Current therapiesStudies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDFKaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis BEarly vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV TransmissionInvestigational functional cure strategiesB-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV InfectionMARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV InfectionREEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBe...
2024-02-0537 minSurfing the MASH TsunamiS4 E50.7 - Wrapping Up 2023 - An Interview with Donna CryerSurfing the MASH Tsunami continues its 2023 wrap-up conversations with Global Liver Institute Founder and CEO Donna Cryer, along with co-hosts Louise Campbell and Roger Green. The conversation focuses on Donna's personal health challenges in late 2023, what her absence revealed about the strength and depth of the GLI team, and what she foresees as major challenges for 2024. The conversation starts with Donna discussing a major medical event in her life during the last few months in 2024, one during which, in her words, "I almost died." She speaks briefly but clearly about the nature of the event itself, as w...
2023-12-2839 minSurfing the MASH TsunamiS4 - E50.1 - Wrapping Up 2023 in Steatotic Liver Disease: A Discussion with Jeff LazarusSurfing the MASH Tsunami kicks off its 2023 wrap-up conversations with Jeff Lazarus, the 2023 winner of the Distinguished Scientific Achievement Award from the American Liver Foundation. He discusses three core MASLD-related opportunities for which he played a key role in 2023: the Research in Action initiative, the new MASLD nomenclature process and the Healthy Livers, Healthy Lives coalition.Most of this discussion focuses on Jeff's work leading the Research in Action coalition. As Jeff notes, this was the first time the MASLD "field has set its own agenda." Absent governmental or not-for-profit agencies driving the discussion, a group that...
2023-12-2031 min
Decera Clinical Education Infectious Disease PodcastSelected FXR Agonist PBC Studies: Conference Coverage of AASLDDuring the 2023 American Association for the Study of Liver Diseases conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-δ agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Kris V. Kowdley MD, FAASLD, FACP, FACG, discusses topline results from several of these studies and more, including: A combination of 3 studies—HEROES, COBALT, and COBALT EC—that evaluated the real-world effectiveness and safety of second-line therapy in PBC where OCA was added to the...
2023-12-1317 min
Decera Clinical Education Infectious Disease PodcastInvestigational PPAR-delta Agonist for PBC Treatment and Race-Based Considerations for PBC Diagnosis: Conference Coverage of AASLDDuring the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Stuart C. Gordon, MD, FAASLD, discusses topline results from one of these late-breaking studies and more, including: A phase III study of an investigational PPAR-delta agonist (seladelpar) in people with PBC who had failed to respond to ursodeoxycholic acidA study that explored r...
2023-12-0709 min
Decera Clinical Education Infectious Disease PodcastInvestigational Dual PPAR Agonist, FXR Agonist With Fibrate, and Hyperlipidemia in People With PBC: Conference Coverage of AASLDDuring the 2023 American Association of the Study of Liver Diseases (AASLD) conference, exciting and important results from many primary biliary cholangitis (PBC) clinical trials were reported, including 3 late-breaking studies on the PPAR-delta agonist seladelpar, the dual PPAR agonist elafibranor, and the combination of the FXR agonist obeticholic acid and a fibrate.In this episode, Marlyn J. Mayo, MD, discusses topline results from several of these studies and more, including: A phase III study of an investigational dual PPAR α/δ agonist (elafibranor) in people with PBC who did not respond to or were intolerant of ursodeoxycholic acid (UDCA)A s...
2023-12-0609 minSurfing the MASH TsunamiS4-E49.1 - TLM2023 Wrap-Up - Panel Discusses General ImpressionsThis conversation between Scott Friedman, Laurent Castera, Louise Campbell and Roger Green covers the four panelists’ general impressions of TLM2023, both the good and bad of it. Scott starts with a simple statement: “It was good to be at an AASLD that felt like an AASLD. Specifically, Scott is talking about the energy and excitement associated with the meeting. He also approves of Boston as a meeting location. Scott’s meeting worst was the meeting app. The group elaborates on why they all agree. Laurent Castera agrees with Scott: bad app; excellent meeting with a great deal of c...
2023-12-0310 min
Decera Clinical Education Infectious Disease PodcastAudio Hepatitis B Update: CCO Independent Conference Coverage of AASLD 2023In this episode, Nancy Reau, MD, discusses new data on hepatitis B virus presented at AASLD 2023, including:Current therapiesStudies 108 and 110: Factors Linked With Lack of Virologic Suppression After 8 Yr of TAF or TDFKaiser Permanente Northern California: HCC or Death With TDF vs ETV for Chronic Hepatitis BEarly vs Late Postpartum Cessation of TDF Initiated for Prevention of Vertical HBV TransmissionInvestigational functional cure strategiesB-Together: Sequential Bepirovirsen and PegIFN Added to NA Therapy for Chronic HBV InfectionMARCH Part B: VIR-3434 ± VIR-2218 ± PegIFN Added to NA Therapy for Chronic HBV InfectionREEF-IT: JNJ-3989 + NA ± JNJ-6379 With PegIFN Add-on Consolidation in Patients With HBe...
2023-11-3037 min
Liver Talks: The Liver Fellow Network PodcastDiving Deep on HCC with Amit SingalOn this episode of Liver Talks, Alex and Adam are joined by Amit Singal, HCC expert and Chief of Hepatology at UT Southwestern, for a fascinating conversation about the latest and greatest in HCC.
Then, a new segment is born featuring Rob Wilechansky, a transplant hepatology fellow at MGH and Hepatology's editorial fellow, in which they discuss an exciting new article from a recent issue of the journal.
AASLD HCC Guideline: https://journals.lww.com/hep/fulltext/9900/aasld_practice_guidance_on_prevention,_diagnosis,.441.aspx
...
2023-10-0349 min
Saúde sem FakeO que é a Hepatite Viral ?O setimo episódio da nova temporada do podcast saúde sem
fake discute Hepatite Viral, um alerta
para prevenir.
fontes:
World Hepatitis
Alliance - World Hepatitis Day (https://www.worldhepatitisalliance.org/world-hepatitis-day
Hepatitis B Foundation - Hepatitis B
Prevention, Screening and Vaccination (https://www.hepb.org/prevention-and-diagnosis/
American Association
for the Study of Liver Diseases (AASLD) - Hepatitis C Guidance (https://www.aasld.org/hepatitis-c)
Centers for Disease
Control and Prevention (CDC) - Testing for Hepatitis B and C (https://www.cdc.gov/hepatitis/statistics/index.htm)
World...
2023-09-2204 min
6 Degrees of Associations: Presented by Big Red M.The Evolution of Membership and Marketing with Camille Sanders, CAE, PCM, CDMAJoining us for today’s episode of 6 Degrees of Associations is Camille Sanders, CAE, PCM, CDMA. Camille currently serves as Senior Director, Career and Workforce Solutions at ASAE: The Center for Association Leadership. Her previous title was as Director, Membership and Marketing with the American Association for the Study of Liver Diseases (AASLD).
AASLD is a preeminent group of healthcare professionals and scientists dedicated to eradicating and preventing liver disease. As a dedicated and accomplished industry expert, this interview explores the evolution of membership and marketing within associations with Camille. From the rise of virtual events to th...
2023-05-3136 minLiver Talks: The Liver Fellow Network PodcastWhat's New in NASH with Mary RinellaThere are new NASH Guidelines and we're gonna talk about them. Who better to chat with than lead author Dr. Mary Rinella? Probably nobody! But first, the precarities of being an NY Jets fan (sorry) and a heads up about the Liver Meeting abstract deadline.
AASLD NASH Guidelines:
https://journals.lww.com/hep/Fulltext/2023/05000/AASLD_Practice_Guidance_on_the_clinical_assessment.31.aspx
Hosts
Adam Winters @adam_c_winters
Alex Vogel @AlexSVogel
Guests:
Mary Rinella @marurinella
2023-05-1631 min
The Emoroid Digest PodcastBaveno VII Guidelines on Portal HTN w/ Dr. Garcia-TsaoIn this episode, we interview two guests, Dr. Guadalupe Garcia Tsao and Dr. Andrew Yu. Dr. Yu is the Emory transplant Hepatology fellow currently. We discuss the Baveno VII guidelines on Portal Hypertension and some major takeaways from #TLM or the American Association for the Study of Liver Diseases (AASLD) meeting in Washington D.C.
Dr. Guadalupe Garcia Tsao is a Professor of Medicine at Yale University School of Medicine and Chief of Digestive Diseases at the VA-Connecticut Healthcare System. She also serves as director of the Clinical Core of the NIH-funded Yale Liver Center and is t...
2023-02-2857 minSurfing the MASH TsunamiS4-E9.2 - What’s Behind The New AACE Fatty Liver Guidelines?This week, SurfingNASH is offering conversation segments to showcase our new series, The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide. Rising Tide, as we call it, is a subscription-only series targeted at the primary care physicians, endocrinologists and allied health professionals who provide front-line treatments for patients living with Type 2 Diabetes and/or obesity. This preview comes from our second episode which focused on the new AACE Fatty Liver Guidelines.The panelists include four authors of the guidelines: first author Dr. Ken Cusi from the University of Florida, third author Dr. Diana Barb, also...
2023-02-2516 minSurfing the MASH TsunamiS4-E7.5 - Introducing the Rising Tide Podcast and Closing Comments on AASLD GuidanceIn the final conversation on AASLD’s new practice guidance, Roger Green contextualizes a new project he is embarking on with Ken Cusi. Together as co-hosts, they will be debuting a new podcast series from next week titled The NASH Tsunami in Diabetes: Getting Ahead of the Rising Tide. The content featured will largely be targeted toward healthcare professionals who treat diabetic patients, the patients themselves and their caregivers. The NAFLD-diabetes dual prevalence is alarmingly high:15% of diabetic patients may have fibrosisIn one study, 70% of diabetics had fatty liver and 35% had NASH25% of deaths in people with NAFLD ar...
2023-02-1212 minSurfing the MASH TsunamiS4-E7.4 - AASLD Practice Guidance and Its Influence Outside of the USLate last week, AASLD published new practice guidance on the clinical assessment and management of NAFLD. The Surfers convene with Ken Cusi, who contributed to the previous iteration published in 2018, to explore its key features and implications. The updated document reflects the many advances pertinent to any practitioner caring for patients with NAFLD. This conversation focuses around the influence the guidance imparts outside of the US.Jörn Schattenberg shares that an EASL guideline commission has been set forward which will refer to the AASLD guidance in supporting its development. Louise comments on the density of information m...
2023-02-1209 minSurfing the MASH TsunamiS4-E7.3 - AASLD Guidance and the Practical Impact on Patients TodayLate last week, AASLD published new practice guidance on the clinical assessment and management of NAFLD. The Surfers convene with Ken Cusi, who contributed to the previous iteration published in 2018, to explore its key features and implications. The updated document reflects the many advances pertinent to any practitioner caring for patients with NAFLD. This conversation focuses on the impact this guidance may have on patients: will it make a difference and if so, how?Ken asserts his position that both patients and providers need to be educated on solutions available today. Measures range from effective diet modifications...
2023-02-1110 minSurfing the MASH TsunamiS4-E7.1 - Introduction to the AASLD Practice Guidance: Impressions and OverviewLate last week, AASLD published new practice guidance on the clinical assessment and management of NAFLD. The Surfers convene with Ken Cusi, who contributed to the previous iteration published in 2018, to explore its key features and implications. The updated document reflects the many advances pertinent to any practitioner caring for patients with NAFLD. This conversation introduces differentiating factors which define a Guidance document versus Guidelines.The conversation starts with Ken introducing the new guidance by placing it in the context of the last five years of thinking about screening and treatment of Fatty Liver patients. He highlights...
2023-02-1111 minSurfing the MASH TsunamiS4-E7 - New 2023 AASLD Practice GuidanceLate last week, AASLD published new practice guidance on the clinical assessment and management of NAFLD. To explore its key features and implications, the surfers convene with Ken Cusi, who contributed to the previous iteration published in 2018. The updated document reflects the many advances pertinent to any practitioner caring for patients with NAFLD. Notably, and as detailed in this episode, it emphasizes advances in noninvasive risk stratification and therapeutics. The group covers at-depth a range of topics to underscore the basis of progress in the field while offering compelling insights on the emerging path forward in combating Fatty Liver...
2023-02-0952 min
Decera Clinical Education Infectious Disease PodcastNewest Viral Hepatitis Data From AASLD 2022In this episode, Stefan Zeuzem, MD, discusses new viral hepatitis data from AASLD 2022, including:Hepatitis BPrevention of HBV vertical transmission when HBIg is unavailableTherapeutic vaccination for HBV cureAntiviral therapy to prevent HCC in patients with CHB in the indeterminate phaseHepatitis deltaHDV prevalence in ethnically diverse, urban, safety-net populationsBulevirtide ± pegIFN-α2a for chronic HDV in the French cATU studyBulevirtide monotherapy for patients with HDV and compensated cirrhosis in the HEP4Di studyHDV functional cure with lonafarnib-based therapyHepatitis CIntegrated community HCV service for PWUD: the ITTREAT studyHelios-3 study of treatment of people with HCV by specialists or nonspecialistsRisk of HCC af...
2022-12-0641 min
Decera Clinical Education Infectious Disease PodcastPractice-Changing Viral Hepatitis Data From AASLD 2022In this episode, Nancy Reau, MD, shares her thoughts on the most practice-changing viral hepatitis data from AASLD 2022, including:Novel therapeutics for HBVHCV management strategiesHDV screening and linkage to careFatty liver disease in persons with viral hepatitisUse of statins to decrease morbidity and mortality in persons with liver diseasePresenter:Nancy Reau, MDProfessor of MedicineChief, Section of HepatologyAssociate DirectorSolid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisLink to full program: https://bit.ly/3Y1tD...
2022-12-0608 minSurfing the MASH TsunamiS3-E54 - AASLD 2022 Liver Meeting Live Coverage: Part 2This week attendees from around the world convened at the 73rd Annual AASLD Liver Meeting for a lively and momentous event in Washington DC. On the final morning, Stephen Harrison, Sven Francque, Jörn Schattenberg, Ian Rowe and Jeff McIntyre join Roger Green to discuss key takeaways. Sven is first to expand on a presentation that struck notable interest. He chooses to highlight a presentation by Laurent Castera, which Mazen Noureddin anticipated in our preview coverage. This focuses on a prospective head-to-head comparison of the different non-invasive tests in a large cohort of T2D patients with NA...
2022-11-101h 34Surfing the MASH TsunamiS3-E53 - AASLD 2022 Liver Meeting Live Coverage: Part 1In an insight-laden conversation recorded on site from Washington DC, Scott Friedman, Jörn Schattenberg, Rachel Zayas and Roger Green discuss takeaways from the first three days at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). The group encapsulates the dynamic, vibrant energy of returning to this momentous event in person:Scott illustrates how progress in the field of Fatty Liver is more a journey of many milestones and not an all-in-one blockbuster conclusion.Rachel injects fascinating new considerations to the podcast through her lens from the microbiome.
2022-11-0747 minSurfing the MASH TsunamiS3-E52.6 - From the Vault: AASLD 2021: The Path To Making NITs the “Gold Standard” for Drug TrialsManal Abdelmalek, Jörn Schattenberg and Ian Rowe join Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from TLMdX 2021, the AASLD annual liver meeting. This conversation focuses on crafting the most robust efficient pathway to shift the gold standard of drug development from semi-quantitative biopsy reads to intelligent use on non-invasive techniques.Opinions diverge about everything from how easy it will be to replace biopsy to exactly what that pathway might look like. What is clear is that everyone in this discussion believes with a hot passion that biopsy is a critical i...
2022-11-0612 minSurfing the MASH TsunamiS3-E52.5 - 2022 AASLD Preview: Final ThoughtsIn a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green to discuss key presentations and posters of interest at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). On November 4th-8th in Washington DC, as many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Ian leads with a reference to the preceding conversation on a poster that describes ways to utilize AI...
2022-11-0609 minSurfing the MASH TsunamiS3-E52 - Part 2: A Preview of the 2022 AASLD Liver MeetingIn a follow-up preview, Jörn Schattenberg, Louise Campbell, Mazen Noureddin, Ian Rowe and patient advocate Jeff McIntyre join Roger Green to discuss key presentations and posters of interest at the 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). On November 4th-8th in Washington DC, as many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care.Mazen begins by highlighting a presentation by Laurent Castera which covers an abstract the two collaborated on. T...
2022-11-0356 minSurfing the MASH TsunamiS3-E51.5 - From the Vault: AASLD 2021 Wrap-upWhen AASLD announced that the 2021 event would be held as a purely virtual meeting, attendees and observers feared a loss of focus and the kind of amplifying energy that comes from being with colleagues. As this episode suggests, the breadth, quality and novelty of the meeting’s presentations generated exceptional positive energy even though colleagues could not meet in person throughout the event. In particular, this group noted the many ways in which the conference format and presentation implicitly challenges some older beliefs and perspectives about NAFLD, NASH and the people who live with these diseases.Surf on...
2022-10-3012 minSurfing the MASH TsunamiS3-E51.3 - AASLD 2022: A Preview of Patient Advocate Coverage on Liver Health EquityThe 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington DC. As many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green to preview key presentations and posters of interest.This conversation starts with Stephen’s comments on the presentation covering fibrosis progression rates for diabetic vs. non-diabetic patients with biopsy-proven NAFL...
2022-10-2912 minSurfing the MASH TsunamiS3-E51 - A Preview of the 2022 AASLD Liver MeetingThe 73rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) takes place on November 4th-8th in Washington DC. As many as 10,000 attendees will convene in an effort to advance and disseminate the science and practice of hepatology, and to promote liver health and quality patient care. In this preview, Key Opinion Leaders Stephen Harrison, Jörn Schattenberg and patient advocate Jeff McIntyre join Roger Green to discuss key presentations and posters of interest.Earlier this month, Stephen and Jörn joined Roger, Louise Campbell and Mazen Noureddin to review a string of...
2022-10-2747 min
Decera Clinical Education Infectious Disease PodcastKey Viral Hepatitis Studies Influencing My Practice Following AASLD 2021In this episode, Nancy Reau, MD, discusses new viral hepatitis data from AASLD 2021, including:HBV treatment in pregnancyOutcomes following HBV treatment withdrawal Progress toward an HBV cureHCV implementation science and current status of the cascade of careHepatitis delta virus: understanding the clinical impactPhase III clinical trial updates for hepatitis delta virus, including data on bulevirtidePresenter: Nancy Reau, MDProfessor of Medicine Chief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisFollow along with the dow...
2021-12-0138 minSurfing the MASH TsunamiS2-E58.1 - Focus On NASH Cirrhosis: Why Cirrhosis Matters and Review of REVERSE Results at AASLDThis episode follows S2 E43 in discussing the possible role of NASH cirrhosis clinical trials in the transition from biopsy as gold standard to a post-biopsy world. Stephen Harrison starts this conversation by discussing why we focus on NASH cirrhosis and goes on to review the recent presentation of results from the REVERSE study on obeticholic acid. Jörn Schattenberg and Mazen Noureddin add their perspectives to the conversation.In this conversation, Stephen starts by pointing out that non-cirrhotic NASH trials and NASH cirrhosis trials differ significantly in goals, endpoints and patient severity. From there, h...
2021-11-2714 minSurfing the MASH TsunamiS2-E57.4 - TLMdX 2021 From AASLD: What Does the Future Hold For NAFLD and NASH?Manal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from the 2021 , the AASLD annual liver meeting. This conversation focuses on complexities and challenges NAFLD drug development and patient treatment will face in the future and ends with predictions about the biggest stories of the 2022 Liver Meeting (hopefully hybrid instead of only digital!).The specific complications include microbiome, which has the potential to add a regional (or even individual) component to our understanding of NAFLD. Stephen Harrison speculates on how the scarcity o...
2021-11-2213 minSurfing the MASH TsunamiS2-E57.3 - 2021 TLMdX From AASLD: Non-conventional efficacy Metrics, Genomics of NAFLD and an Exciting FutureManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from the 2021 TLMdX, the AASLD annual liver meeting. This conversation focuses how to make NITs the "gold standard" of drug development instead of biopsy.The guests is Antaros Medical Chief Scientific Officer and recent SurfingNASH (S2 E50) panelist Lars Johansson, who joins the discussion from the audience to ask about use of spleen volume as a surrogate measure in F2 and F3, the value using AI models to re-evaluate old imaging data a...
2021-11-2112 minSurfing the MASH TsunamiS2-E57.2 - 2021 TLMdX From AASLD: The Path To Making NITs the "Gold Standard" for Drug TrialsManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from the 2021 TLMdX, the AASLD annual liver meeting. This conversation focuses on crafting the most robust efficient pathway to shift the gold standard of drug development from semi-quantitative biopsy reads to intelligent use on non-invasive techniques.Opinions diverge about everything from how easy it will be to replace biopsy to exactly what that pathway might look like. What is clear is that everyone in this discussion believes with a hot passion that biopsy is a...
2021-11-2112 minSurfing the MASH TsunamiS2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASHManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from the 2021 TLMdX, the AASLD annual liver meeting. This conversation focuses on what we have learned about NITs and clinical development testing that will, in the words of Stephen Harrison, "put a big, fat dent in Fatty Liver disease."The conversation starts with the group congratulating Manal Abdelmalek on her wrap-up NAFLD talk at the 2021 TLMdX. From there, the group focuses on the shortcomings of using biopsy as the clinical trial gold standard and h...
2021-11-2118 minSurfing the MASH TsunamiS2-E57 - AASLD 2021 Wrap-up: Looking Back on an Eventful TLMdXManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap this week's just-concluded TLMdX 2021, the AASLD annual liver meeting. When AASLD announced that the 2021 TLMdX would be held as a purely virtual meeting, attendees and observers feared a loss of focus and the kind of amplifying energy that comes from being with colleagues. That did not happen. Instead, the breadth, quality and novelty of the meeting's presentations generated exceptional positive energy despite the virtual setting. 4:10 - Roger starts by saluting Manal for giving the NAFLD Wrap-up Tal...
2021-11-191h 02Surfing the MASH TsunamiS2-E56 - Day Four at the 2021 TLMdX From AASLDDrs. Michael Charlton and Mazen Noureddin and Global Liver Institute Director of Global NASH Programs Jeff McIntyre join Dr. Stephen Harrison, Louise Campbell and Roger Green to review some of the most important and exciting presentations from the final two days of the 2021 TLMdX, the annual meeting of AASLD. Each panelist chose 1-2 presentations or posters from the 2021 TLMdX from AASLD that they thought conveyed a major topic or question in the meeting. The group discussed each paper, sometimes moving far afield the original topic. As usual with SurfingNASH, conversations were interspersed with challenging insights and comments, d...
2021-11-161h 50Surfing the MASH TsunamiS2-E55 - Day Three at the 2021 TLMdX From AASLDProfs. Scott Friedman and Michelle Long, Dr. Naim Alkhouri and Global Liver Institute DIrector of Global NASH Programs Jeff McIntyre join Louise Campbell and Roger Green to review some of the most important and exciting presentations from the first three days of the 2021 TLMdX, the annual meeting from AASLD.Description: Each panelist chose 1-2 presentations or posters from the 2021 TLMdX from AASLD that they thought conveyed a major topic or question in the meeting. The group discussed each paper, sometimes moving far afield the original topic. As usual with SurfingNASH, conversations were interspersed with challenging i...
2021-11-151h 46Surfing the MASH TsunamiS2-E53.3 - AASLD 2021 Preview: NASH Patient Management Topics Range From Drugs In Development To Applied Day-to-Day Issues In the third conversation from SurfingNASH's AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss a range of issues in the later days of the conference, all loosely related to NASH Patient Management.Jörn starts this conversation by identifying some of the important presentations on clinical trials of novel therapies. From here, the group focuses on other Sunday and Monday presentations, some with a basic science focus and others that are more patient-oriented. In the end, the group answers Roger's final question, "If there's one imp...
2021-11-0714 minSurfing the MASH TsunamiS2-E57.1 - 2021 TLMdX from AASLD: Putting a "Big, Fat Dent" in NAFLD and NASHManal Abdelmalek, Jörn Schattenberg and Ian Rowe join regulars Stephen Harrison, Louise Campbell and Roger Green to recap NAFLD and NASH-related insights from the 2021 TLMdX, the AASLD annual liver meeting. This conversation focuses on what we have learned about NITs and clinical development testing that will, in the words of Stephen Harrison, "put a big, fat dent in Fatty Liver disease."The conversation starts with the group congratulating Manal Abdelmalek on her wrap-up NAFLD talk at the 2021 TLMdX. From there, the group focuses on the shortcomings of using biopsy as the clinical t...
2021-11-0718 minSurfing the MASH TsunamiS2-E53.2 - AASLD 2021 Preview: A Weekend of Broad NASH Disease/Drug Management CoverageIn the second conversation from SurfingNASH's AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss the breadth of NASH Drug/Disease Management on the weekend agenda.Louise starts this conversation by pointing out Saturday sessions she believes will be important to understanding Fatty Liver care delivery, including sessions addressing women's health, health service and public health. From there, Ken leads into a discussion of Saturday's post-graduate course and Manal Abdelmalek opens a discussion on Sunday's Presidential Plenary session. She and Jörn note the importance of th...
2021-11-0612 minSurfing the MASH TsunamiS2-E53.1 - AASLD 2021 Preview: Presentations on Basic NASH ScienceIn the first conversation from SurfingNASH's AASLD 2021 preview, Manal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to focus on some of the basic NASH Science presentations during the first two days of the meeting.After some preliminary comments from Roger and others about Saturday's day-long post-graduate course in NAFLD and NASH, Manal kicks this session into high gear by highlighting the Hans Popper Basic Science State-of-the-Art lecture, with its focus on single-cell genomics and its ability to transform our understanding of disease pathogenesis. As Manal points out, this becomes t...
2021-11-0615 minSurfing the MASH TsunamiS2-E53 - SurfingNASH Previews AASLD 2021: the Digital Liver MeetingManal Abdelmalek, Ken Cusi and Jörn Schattenberg join Louise Campbell and Roger Green to discuss key presentations at AASLD 2021 and preview SurfingNASH's coverage of the event. This virtual meeting runs from November 12-15 and is scheduled on East Coast time.Highlights include:9:19 – Roger begins the conversation, by describing the AASLD program elements and what SurfingNASH will cover.10:46 – Manal Abdelmalek kicks us off by focusing on Dr. Neil Henderson’s Hans Popper (Basic State of Science) Lecture and the relevance his talk will have meaning for NAFLD and NASH.12:53 – Ken Cusi links this talk...
2021-11-0449 min
BackTable Vascular & InterventionalEp. 127 Portal Hypertension and Ascites Management with Hepatologist Dr. Parvez MantryInterventional Radiologist Christopher Beck talks with Hepatologist Parvez Mantry about the management of Portal Hypertension and Ascites, and the importance of multi-disciplinary collaborative care for these patients.---SHOW NOTESIn this episode, hepatologist Dr. Parvez Mantry joins our host Dr. Christopher Beck to discuss portal hypertension and ascites, two complications that arise from liver diseases and have a large effect on patients’ quality of life.Dr. Mantry starts the episode by sharing statistics on Chronic Liver Disease (CLD) an...
2021-05-1750 min
Decera Clinical Education Infectious Disease PodcastViral Hepatitis Data From AASLD 2020 – Rapid RecapIn this episode, Dr. Terrault discusses results from key viral hepatitis studies reported at the American Association for the Study of LiverDiseases (AASLD) 2020 annual conference, The Liver Meeting Digital Experience, including new findings on HBV treatment and management, hepatocellular carcinoma risk, and emerging approaches to HCV care in underserved populations.Presenter:Norah Terrault, MD, MPHProfessor of MedicineChief of Gastrointestinal and Liver DiseasesUniversity of Southern CaliforniaLos Angeles, CaliforniaContent based on a CME program supported by an independent educational grant from Gilead Sciences, Inc.L...
2020-11-2550 min
BackTable Vascular & InterventionalEp. 87 Deep Dive Into Ascites with Dr. Rajeev SuriIn this episode, Dr. Rajeev Suri joins Dr. Christopher Beck to discuss ascites and paracentesis. Dr. Suri touches on what a potential paracentesis candidate might present with and speaks about why no lab values or blood tests are needed prior to the procedure. We discuss the basic steps for removing ascites, how to find the side with the biggest pocket, and preventing leakage by using a Z pattern. He speaks to the circumstances for using direct US guidance rather than intermittent and when, if ever, to use glue or stitches after paracentesis. We mention the benefits of utilizing the...
2020-10-0640 min
GastroenterologiaSteatoepatite non alcolica, domani si celebra l'"International Nash Day" patrocinata da AASLD e EASLIl 12 giugno si celebra la Giornata Mondiale sulla NASH che quest'anno per la prima volta è patrocinata da AASLD ed EASL.Ci siamo fatti spiegare dalla dr.ssa Livia Alimena come è sono organizzati i vari incontri dal Global Liver Institute e quali sono gli altri loro progetti importanti.
2020-06-1109 min
HEPATOLOGY PodcastThe Severity Of Steatosis Influences Liver Stiffness Measurement In Patients With NAFLDDrs. Stephen A. Harrison and Salvatore Petta discuss the paper: The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease from the November 2015 issue of HEPATOLOGY.
2016-01-1207 min
eViralHepatitis ReviewAdvances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015Volume 4, Issue 3, Part 3. Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Gregory Dore from the Kirby Institute, UNSW Australia about the C-EDGE CO-STAR study.
The post Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015 appeared first on DKBmed Radio.
2015-12-2900 mineViralHepatitis ReviewAdvances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015Volume 4, Issue 3, Part 2. Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Graham Foster from Queen Mary University of London about the ASTRAL-3 study.
The post Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015 appeared first on DKBmed Radio.
2015-12-2900 mineViralHepatitis ReviewAdvances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015Volume 4, Issue 3, Part 1. Mark S. Sulkowski from the Johns Hopkins University School of Medicine interviews Dr. Vincent Leroy from Grenoble University Hospital about the ALLY-3+ study.
The post Advances in Managing Hard-to-Treat Hepatitis C: Highlights from the American Association for the Study of Liver Diseases (AASLD) Meeting November 2015 appeared first on DKBmed Radio.
2015-12-2900 minHEPATOLOGY PodcastLedipasvir/Sofosbuvir Safety+Tolerability With&Without Ribavirin in Chronic HCV InfectionNote: Published earlier in 2015.
Drs. Stephen A. Harrison and Saleh A. Alqahtani discuss the paper: Safety and Tolerability of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Phase III ION Trials.
2015-11-3010 minHEPATOLOGY PodcastAssociation of NAFLD with Subclinical Myocardial Remodeling and DysfunctionDrs. Stephen A. Harrison and Lisa B. VanWagner discuss the paper: Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study.
2015-09-1711 minHEPATOLOGY PodcastThe Role of Hepatic Resection in Liver CancerDrs. Stephen A. Harrison and Sasan Roayaie discuss the paper: The Role of Hepatic Resection in the Treatment of Hepatocellular Cancer.
2015-09-1011 minHEPATOLOGY PodcastLedipasvir/Sofosbuvir Safety+Tolerability With&Without Ribavirin in Chronic HCV InfectionDrs. Stephen A. Harrison and Saleh A. Alqahtani discuss the paper: Safety and Tolerability of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Phase III ION Trials.
2015-07-3010 minHEPATOLOGY PodcastThe Impact of Phlebotomy in Nonalcoholic Fatty Liver DiseaseDrs. Stephen A. Harrison and Leon A. Adams discuss the paper: The Impact of Phlebotomy in Nonalcoholic Fatty Liver Disease: A Prospective, Randomized, Controlled Trial.
2015-06-2311 minHEPATOLOGY PodcastPortal Hypertension and the Outcome of Surgery for HCCDrs. Stephen A. Harrison and Annalisa Berzigotti discuss the paper: Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta-analysis from the Februrary issue of HEPATOLOGY.
2015-01-2311 minHEPATOLOGY PodcastConcordance Of Sustained Virological Response With Sofosbuvir - Containing Regimens For HCVDrs. Stephen A. Harrison and Eric M. Yoshida discuss the paper: Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus from the January issue of HEPATOLOGY.
2015-01-1507 minHEPATOLOGY PodcastPrioritizing HCC Patients -- Results Of The UNOS National Geographic ExperimentDrs. Stephen A. Harrison and Karim J. Hazalun discuss the paper: Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment from the December issue of HEPATOLOGY.
2015-01-1506 minHEPATOLOGY PodcastEnhanced MRI Prognosis Of Early Early Stage HCCStephen A. Harrison, MD and Taro Yamashita, MD, PhD, discuss Gd-EOB-DTPA-enhanced MRI and Alpha-fetoprotein Predict Prognosis of Early Early Stage HCC.
2015-01-1510 minHEPATOLOGY PodcastUrsodeoxycholic Acid and PSC, RevisitedUrsodeoxycholic acid (UDCA) is no longer recommended for management of adult patients with primary sclerosing cholangitis (PSC). We undertook a prospective evaluation of UDCA withdrawal in a group of consecutive patients with PSC. Twenty six patients, all treated with UDCA (dose range: 10-15 mg/kg/day) were included. Paired blood samples for liver biochemistry, bile acids, and fibroblast growth factor 19 (FGF19) were collected before UDCA withdrawal and 3 months later. Liquid chromatography/tandem mass spectrometry was used for quantification of 29 plasma bile acid metabolites. Pruritus and health-related quality of life (HRQoL) were assessed with a 10-point numeric rating scale, the Medical...
2014-10-3109 minHEPATOLOGY PodcastKidney Biomarkers and Differential Diagnosis of Patients with Cirrhosis and Acute Kidney InjuryAcute kidney injury (AKI) is common in patients with cirrhosis and associated with significant mortality. The most common etiologies of AKI in this setting are prerenal azotemia (PRA), acute tubular necrosis (ATN), and hepatorenal syndrome (HRS). Accurately distinguishing the etiology of AKI is critical, as treatments differ markedly. However, establishing an accurate differential diagnosis is extremely challenging. Urinary biomarkers of kidney injury distinguish structural from functional causes of AKI and may facilitate more accurate and rapid diagnoses. We conducted a multicenter, prospective cohort study of patients with cirrhosis and AKI assessing multiple biomarkers for differential diagnosis of clinically adjudicated AKI...
2014-08-2717 minHEPATOLOGY PodcastNASH and HCC: A Growing Role for Liver TransplantationNonalcoholic steatohepatitis (NASH) is currently the third leading indication for liver transplantation (LT) in the U.S. and is predicted to become the leading indication for LT in the near future. The trends in NASH-related hepatocellular carcinoma (HCC) among LT recipients in the U.S. remain undefined. We performed a retrospective cohort study to evaluate trends in the etiology of HCC among adult LT recipients in the U.S. from 2002 to 2012, using national data from the United Network for Organ Sharing registry. From 2002-2012, there were 61,868 adults who underwent LT in the U.S., including 10,061 patients with HCC. The total...
2014-07-1010 minHEPATOLOGY PodcastDistinguishing Immunoglobulin G4-associated Cholangitis from PSCThe recent addition of immunoglobulin (Ig)G4-associated cholangitis (IAC), also called IgG4-related sclerosing cholangitis (IRSC), to the spectrum of chronic cholangiopathies has created the clinical need for reliable methods to discriminate between IAC and the more common cholestatic entities, primary (PSC) and secondary sclerosing cholangitis. The current American Association for the Study of Liver Diseases practice guidelines for PSC advise on the measurement of specific Ig (sIg)G4 in PSC patients, but interpretation of elevated sIgG4 levels remains unclear. We aimed to provide an algorithm to distinguish IAC from PSC using sIgG analyses. We measured total IgG and...
2014-05-3013 minHEPATOLOGY PodcastAscites: Is the Etiology Cirrhosis or Cardiac?Heart failure (HF) is, after cirrhosis, the second-most common cause of ascites. Serum B-type natriuretic peptide (BNP) plays an important role in the diagnosis of HF. Therefore, we hypothesized that BNP would be useful in the differential diagnosis of ascites. Consecutive patients with new onset ascites were prospectively enrolled in this cross-sectional study. All patients had measurements of serum-ascites albumin gradient (SAAG), total protein concentration in ascitic fluid, serum, and ascites BNP. We enrolled 218 consecutive patients with ascites resulting from HF (n = 44), cirrhosis (n = 162), peritoneal disease (n = 10), and constrictive pericarditis (n = 2). Compared to SAAG and/or total protein concentration in...
2014-04-0212 mineViralHepatitis ReviewSusanna Naggie, MD Discussed HBV and HCV Coverage at AASLDVolume 3, Issue 8. Susanna Naggie, MD, Professor, Assistant Professor of Medicine, Department of Medicine – Infectious Diseases at Duke University School of Medince discusses the development of new therapies for treating hepatitis C infection, and news about hepatitis B from the 64th meeting of the American Association for the Study of Liver Disease, as …
Continue reading "Susanna Naggie, MD Discussed HBV and HCV Coverage at AASLD"
The post Susanna Naggie, MD Discussed HBV and HCV Coverage at AASLD appeared first on DKBmed Radio.
2014-03-3100 min
HEPATOLOGY PodcastSteroid Use In Acute Liver FailureExtensive population-based studies are much needed to accurately establish epidemiology and disease course in patients with primary sclerosing cholangitis (PSC). We aimed to obtain population-based prevalence and incidence figures, insight in disease course with regard to survival, liver transplantation (LT), and occurrence of malignancies, as well as risk factors thereof. Four independent hospital databases were searched in 44 hospitals in a large geographically defined area of the Netherlands, comprising 50% of the population. In addition, all PSC patients in the three Dutch liver transplant centers and all inflammatory bowel disease (IBD) patients in the adherence area of a large district hospital were...
2014-02-2717 minHEPATOLOGY PodcastSclerosingcholangitisExtensive population-based studies are much needed to accurately establish epidemiology and disease course in patients with primary sclerosing cholangitis (PSC). We aimed to obtain population-based prevalence and incidence figures, insight in disease course with regard to survival, liver transplantation (LT), and occurrence of malignancies, as well as risk factors thereof. Four independent hospital databases were searched in 44 hospitals in a large geographically defined area of the Netherlands, comprising 50% of the population. In addition, all PSC patients in the three Dutch liver transplant centers and all inflammatory bowel disease (IBD) patients in the adherence area of a large district hospital were...
2013-12-1312 minHEPATOLOGY PodcastCross-talk between Notch and Hedgehog Regulates Hepatic Stellate Cell Fate in MiceLiver repair involves phenotypic changes in hepatic stellate cells (HSCs) and reactivation of morphogenic signaling pathways that modulate epithelial-to-mesenchymal/mesenchymal-to-epithelial transitions, such as Notch and Hedgehog (Hh). Hh stimulates HSCs to become myofibroblasts (MFs). Recent lineage tracing studies in adult mice with injured livers showed that some MFs became multipotent progenitors to regenerate hepatocytes, cholangiocytes, and HSCs. We studied primary HSC cultures and two different animal models of fibrosis to evaluate the hypothesis that activating the Notch pathway in HSCs stimulates them to become (and remain) MFs through a mechanism that involves an epithelial-to-mesenchymal–like transition and requires cross-talk with th...
2013-12-0312 minHEPATOLOGY PodcastMinimal Hepatic Encephalopathy: Making Diagnosis EasierMinimal Hepatic Encephalopathy: Making Diagnosis Easier by AASLD
2013-10-0412 minHEPATOLOGY PodcastPredictive Models of Cirrhosis and HCC in CHBIntegrating host and HBV characteristics, this study aimed to develop models for predicting long-term cirrhosis and hepatocellular carcinoma (HCC) risk in chronic hepatitis B virus (HBV) patients. This analysis included hepatitis B surface antigen (HBsAg)-seropositive and anti-HCV-seronegative participants from the Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (R.E.V.E.A.L.-HBV) cohort. Newly developed cirrhosis and HCC were ascertained through regular follow-up ultrasonography, computerized linkage with national health databases, and medical chart reviews. Two-thirds of the participants were allocated for risk model derivation and another one-third for model validation. The...
2013-09-1316 minHEPATOLOGY PodcastGood long-term Outcome of Budd-Chiari Syndrome with a Step-wise ManagementDrs. Stephen Harrison and Susana Seijo
Budd-Chiari syndrome (BCS) is a rare, life-threatening disease caused by obstruction of hepatic venous outflow. The aim of the study was to assess long-term outcome and identify prognostic factors in BCS patients managed by a step-wise approach using anticoagulation, angioplasty/thrombolysis, transjugular intrahepatic portosystemic shunting (TIPS), and orthotopic liver transplantation (OLT). We reviewed long-term data on 157 patients previously included by the European Network for Vascular Disorders of the Liver, a multicenter prospective study of newly diagnosed BCS patients in nine European countries. Patients were followed for a median of 50 months (range, 0.1-74.0). During the...
2013-06-2516 minHEPATOLOGY PodcastResection of Hepatocellular Cancer ≤2 cm: Results from Two Western CentersDrs. Stephen Harrison and Sasan Roayaie
Asian series have shown a 5-year survival rate of ˜70% after resection of hepatocellular carcinoma (HCC) =2 cm. Western outcomes with resection have not been as good. In addition, ablation of HCC =2 cm has been shown to achieve competitive results, leaving the role of resection in these patients unclear. Records of patients undergoing resection at two Western centers between January 1990 and December 2009 were reviewed. Patients with a single HCC =2 cm on pathologic analysis were included. Thirty clinical variables including demographics, liver function, tumor characteristics, nature of the surgery, and the surrounding liver were examined. An exploratory s...
2013-04-2615 minHEPATOLOGY PodcastVitamin A Deficiency and Hepatitis CDrs. Stephen A. Harrison and Davide Bitetto
Recent data suggest that vitamin A modulates the expression of type I interferon receptor enhancing the antireplication effect of interferon-α on hepatitis C virus (HCV). This study aimed to investigate the prevalence of vitamin A deficiency among patients with chronic HCV infection and to assess whether vitamin A deficiency could be associated with unresponsiveness to interferon-based antiviral therapy. The analysis included 199 consecutive treatment-naïve chronic HCV patients in whom pretreatment serum vitamin A and 25-OH vitamin D were measured; 119 healthy blood donors were used as controls. Median (interquartile range) serum vitamin A in HC...
2013-04-0913 minHEPATOLOGY PodcastSexual Transmission of Hepatitis CDrs. Stephen A. Harrison and Norah A. Terrault
The efficiency of hepatitis C virus (HCV) transmission by sexual activity remains controversial. We conducted a cross-sectional study of HCV-positive subjects and their partners to estimate the risk for HCV infection among monogamous heterosexual couples. A total of 500 anti–HCV-positive, human immunodeficiency virus–negative index subjects and their long-term heterosexual partners were studied. Couples were interviewed separately for lifetime risk factors for HCV infection, within-couple sexual practices, and sharing of personal grooming items. Blood samples were tested for anti-HCV, HCV RNA, and HCV genotype and serotype. Sequencing and phylogenetic analysis determined the rela...
2013-04-0916 minHEPATOLOGY PodcastAcute Kidney Injury and Hospitalized CirrhoticsDrs. Stephen A. Harrison and Justin A. Belcher
Acute kidney injury (AKI) is a common and devastating complication in patients with cirrhosis. However, the definitions of AKI employed in studies involving patients with cirrhosis have not been standardized, lack sensitivity, and are often limited to narrow clinical settings. We conducted a multicenter, prospective observational cohort study of patients with cirrhosis and AKI, drawn from multiple hospital wards, utilizing the modern acute kidney injury network (AKIN) definition and assessed the association between AKI severity and progression with in-hospital mortality. Of the 192 patients who were enrolled and included in the study, 85 (44%) progressed...
2013-04-0915 minHEPATOLOGY PodcastA New Non-invasive Test for NASHDrs. Stephen Harrison and Sudeep Tanwar
Liver biopsy is the reference standard for the detection of nonalcoholic steatohepatitis (NASH) within nonalcoholic fatty liver disease (NAFLD). The aim of this study was to identify a biomarker of NASH in patients without significant fibrosis. In all, 172 patients from two centers with biopsy-proven NAFLD were included in this study. Eighty-four patients from a single center were included as a derivation cohort and 88 patients from a second center were included as a validation cohort. Serum samples were tested for candidate markers of fibrosis and inflammation alongside hematological and biochemical markers. Among patients without advanced...
2013-01-2814 minHEPATOLOGY PodcastSignificance of Azathioprine Metabolites for the Maintenance of Remission in Autoimmune HepatitisDrs. Stephen Harrison and Harpreet Dhaliwal
Azathioprine (AZA) is used to maintain remission in autoimmune hepatitis (AIH), but up to 18% of patients are unresponsive. AZA is a prodrug, and the formation of active thioguanine nucleotide (TGN) metabolites varies widely. We aimed to assess the relationship between AZA metabolite concentrations (i.e., TGNs and methylmercaptopurine nucleotides [MeMPNs]), thiopurine methyltransferase (TPMT) activity, therapeutic response, and toxicity in adult patients with AIH prescribed a stable dose of AZA for the maintenance of remission. Red blood cell (RBC) TGNs and MeMPNs were measured in serial blood samples over a 2-year period. The average TGNs...
2012-12-1811 minHEPATOLOGY PodcastImpact of disease severity on healthcare costs in patients with HCVAbstract
Hepatitis C virus (HCV) infection increases total healthcare costs but the effect of the severity of liver disease associated with chronic hepatitis C (CHC) on healthcare costs has not been well studied. We analyzed the demographics, healthcare utilization, and healthcare costs of CHC patients in a large U.S. private insurance database (January, 2002 to August, 2010), with at least 1 year of baseline enrollment and 30 days of continuous follow-up. Patients were stratified by liver disease severity: noncirrhotic liver disease (NCD), compensated cirrhosis (CC), and endstage liver disease (ESLD), as defined by the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9...
2012-12-0312 minHEPATOLOGY PodcastActivation of IKK/NFκB signaling induces liver fibrosisDr. Stephen Harrison talks to Drs. Thomas Wirth and Yoshiaki Suname about the paper: Hepatic activation of IKK/NFκB signaling induces liver fibrosis via macrophage-mediated chronic inflammation
Abstract:
Liver damage in humans is induced by various insults including alcohol abuse, hepatitis B/C virus infection, autoimmune or metabolic disorders and, when persistent, leads to development of liver fibrosis. Because the nuclear factor-κB (NF-κB) system is activated in response to several of these stresses, we hypothesized that NF-κB activation in hepatocytes may contribute to fibrosis development. To activate the NF-κB signaling pathway in a time- and cell...
2012-10-0408 minHEPATOLOGY PodcastModel to estimate survival in ambulatory patients with hepatocellular carcinomaDrs. Stephen Harrison and W. Ray Kim discuss the paper: Model to estimate survival in ambulatory patients with hepatocellular carcinoma
Abstract
Survival of patients with hepatocellular carcinoma (HCC) is determined by the extent of the tumor and the underlying liver function. We aimed to develop a survival model for HCC based on objective parameters including the Model for Endstage Liver Disease (MELD) as a gauge of liver dysfunction. This analysis is based on 477 patients with HCC seen at Mayo Clinic Rochester between 1994 and 2008 (derivation cohort) and 904 patients at the Korean National Cancer Center between 2000 and 2003 (validation cohort). Multivariate proportional hazards...
2012-10-0412 min